BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Frank AK, Leu JI, Zhou Y, Devarajan K, Nedelko T, Klein-Szanto A, Hollstein M, Murphy ME. The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation. Mol Cell Biol 2011;31:1201-13. [PMID: 21245379 DOI: 10.1128/MCB.01136-10] [Cited by in Crossref: 70] [Cited by in F6Publishing: 55] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Barnoud T, Parris JLD, Murphy ME. Common genetic variants in the TP53 pathway and their impact on cancer. J Mol Cell Biol 2019;11:578-85. [PMID: 31152665 DOI: 10.1093/jmcb/mjz052] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
2 Wagner T, Kiweler N, Wolff K, Knauer SK, Brandl A, Hemmerich P, Dannenberg JH, Heinzel T, Schneider G, Krämer OH. Sumoylation of HDAC2 promotes NF-κB-dependent gene expression. Oncotarget 2015;6:7123-35. [PMID: 25704882 DOI: 10.18632/oncotarget.3344] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
3 Alam MJ, Bardakci F, Anjum S, Mir SR, Ahmad I, Saeed M. Molecular docking analysis of p53 with Toll-like receptors. Bioinformation 2021;17:784-9. [PMID: 35539888 DOI: 10.6026/97320630017784] [Reference Citation Analysis]
4 Budina-Kolomets A, Barnoud T, Murphy ME. The transcription-independent mitochondrial cell death pathway is defective in non-transformed cells containing the Pro47Ser variant of p53. Cancer Biol Ther 2018;19:1033-8. [PMID: 30010463 DOI: 10.1080/15384047.2018.1472194] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
5 Pavlakis E, Stiewe T. p53's Extended Reach: The Mutant p53 Secretome. Biomolecules 2020;10:E307. [PMID: 32075247 DOI: 10.3390/biom10020307] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
6 Cho JH, Patel B, Bonala S, Mansouri H, Manne S, Vadrevu SK, Ghouse S, Kung CP, Murphy ME, Astrinidis A, Henske EP, Kwiatkowski DJ, Markiewski MM, Karbowniczek M. The Codon 72 TP53 Polymorphism Contributes to TSC Tumorigenesis through the Notch-Nodal Axis. Mol Cancer Res 2019;17:1639-51. [PMID: 31088907 DOI: 10.1158/1541-7786.MCR-18-1292] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
7 Wasserman JD, Zambetti GP, Malkin D. Towards an understanding of the role of p53 in adrenocortical carcinogenesis. Mol Cell Endocrinol 2012;351:101-10. [PMID: 21930187 DOI: 10.1016/j.mce.2011.09.010] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
8 Jennis M, Kung CP, Basu S, Budina-Kolomets A, Leu JI, Khaku S, Scott JP, Cai KQ, Campbell MR, Porter DK, Wang X, Bell DA, Li X, Garlick DS, Liu Q, Hollstein M, George DL, Murphy ME. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev 2016;30:918-30. [PMID: 27034505 DOI: 10.1101/gad.275891.115] [Cited by in Crossref: 136] [Cited by in F6Publishing: 139] [Article Influence: 22.7] [Reference Citation Analysis]
9 Endo F, Nishizuka SS, Kume K, Ishida K, Katagiri H, Ishida K, Sato K, Iwaya T, Koeda K, Wakabayashi G. A compensatory role of NF-κB to p53 in response to 5-FU-based chemotherapy for gastric cancer cell lines. PLoS One. 2014;9:e90155. [PMID: 24587255 DOI: 10.1371/journal.pone.0090155] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
10 Budina-Kolomets A, Webster MR, Leu JI, Jennis M, Krepler C, Guerrini A, Kossenkov AV, Xu W, Karakousis G, Schuchter L, Amaravadi RK, Wu H, Yin X, Liu Q, Lu Y, Mills GB, Xu X, George DL, Weeraratna AT, Murphy ME. HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Res 2016;76:2720-30. [PMID: 26984758 DOI: 10.1158/0008-5472.CAN-15-2137] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
11 Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer. 2013;12:86. [PMID: 23915189 DOI: 10.1186/1476-4598-12-86] [Cited by in Crossref: 1589] [Cited by in F6Publishing: 1573] [Article Influence: 176.6] [Reference Citation Analysis]
12 Lowe JM, Menendez D, Bushel PR, Shatz M, Kirk EL, Troester MA, Garantziotis S, Fessler MB, Resnick MA. p53 and NF-κB coregulate proinflammatory gene responses in human macrophages. Cancer Res 2014;74:2182-92. [PMID: 24737129 DOI: 10.1158/0008-5472.CAN-13-1070] [Cited by in Crossref: 92] [Cited by in F6Publishing: 66] [Article Influence: 11.5] [Reference Citation Analysis]
13 Synoradzki KJ, Bartnik E, Czarnecka AM, Fiedorowicz M, Firlej W, Brodziak A, Stasinska A, Rutkowski P, Grieb P. TP53 in Biology and Treatment of Osteosarcoma. Cancers (Basel) 2021;13:4284. [PMID: 34503094 DOI: 10.3390/cancers13174284] [Reference Citation Analysis]
14 Rodríguez-Lara SQ, Cardona-Muñoz EG, Ramírez-Lizardo EJ, Totsuka-Sutto SE, Castillo-Romero A, García-Cobián TA, García-Benavides L. Alternative Interventions to Prevent Oxidative Damage following Ischemia/Reperfusion. Oxid Med Cell Longev 2016;2016:7190943. [PMID: 28116037 DOI: 10.1155/2016/7190943] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
15 Kung CP, Leu JI, Basu S, Khaku S, Anokye-Danso F, Liu Q, George DL, Ahima RS, Murphy ME. The P72R Polymorphism of p53 Predisposes to Obesity and Metabolic Dysfunction. Cell Rep 2016;14:2413-25. [PMID: 26947067 DOI: 10.1016/j.celrep.2016.02.037] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 11.5] [Reference Citation Analysis]
16 Weige CC, Birtwistle MR, Mallick H, Yi N, Berrong Z, Cloessner E, Duff K, Tidwell J, Clendenning M, Wilkerson B, Farrell C, Bunz F, Ji H, Shtutman M, Creek KE, Banister CE, Buckhaults PJ. Transcriptomes and shRNA suppressors in a TP53 allele-specific model of early-onset colon cancer in African Americans. Mol Cancer Res 2014;12:1029-41. [PMID: 24743655 DOI: 10.1158/1541-7786.MCR-13-0286-T] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
17 Loeb KR, Asgari MM, Hawes SE, Feng Q, Stern JE, Jiang M, Argenyi ZB, de Villiers EM, Kiviat NB. Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas. PLoS One 2012;7:e34422. [PMID: 22545084 DOI: 10.1371/journal.pone.0034422] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
18 Lodhi N, Singh R, Rajput SP, Saquib Q. SARS-CoV-2: Understanding the Transcriptional Regulation of ACE2 and TMPRSS2 and the Role of Single Nucleotide Polymorphism (SNP) at Codon 72 of p53 in the Innate Immune Response against Virus Infection. Int J Mol Sci 2021;22:8660. [PMID: 34445373 DOI: 10.3390/ijms22168660] [Reference Citation Analysis]
19 Azzam G, Wang X, Bell D, Murphy ME. CSF1 is a novel p53 target gene whose protein product functions in a feed-forward manner to suppress apoptosis and enhance p53-mediated growth arrest. PLoS One 2013;8:e74297. [PMID: 24019961 DOI: 10.1371/journal.pone.0074297] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
20 Gebert M, Jaśkiewicz M, Moszyńska A, Collawn JF, Bartoszewski R. The Effects of Single Nucleotide Polymorphisms in Cancer RNAi Therapies. Cancers (Basel) 2020;12:E3119. [PMID: 33113880 DOI: 10.3390/cancers12113119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Gao Y, Su YP, Li XL, Lei SJ, Chen HF, Cui SY, Zhang SF, Zou JM, Liu QJ, Sun QF. ATM and TP53 Polymorphisms Modified Susceptibility to Radiation-Induced Lens Opacity in Natural High Background Radiation Area, China. Int J Radiat Biol 2022;:1-28. [PMID: 34995174 DOI: 10.1080/09553002.2022.2024294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Iannetti A, Ledoux AC, Tudhope SJ, Sellier H, Zhao B, Mowla S, Moore A, Hummerich H, Gewurz BE, Cockell SJ, Jat PS, Willmore E, Perkins ND. Regulation of p53 and Rb links the alternative NF-κB pathway to EZH2 expression and cell senescence. PLoS Genet 2014;10:e1004642. [PMID: 25255445 DOI: 10.1371/journal.pgen.1004642] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 7.9] [Reference Citation Analysis]
23 Sabatel H, Di Valentin E, Gloire G, Dequiedt F, Piette J, Habraken Y. Phosphorylation of p65(RelA) on Ser(547) by ATM represses NF-κB-dependent transcription of specific genes after genotoxic stress. PLoS One 2012;7:e38246. [PMID: 22715377 DOI: 10.1371/journal.pone.0038246] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
24 Su C, Lin Y, Niu J, Cai L. Association between polymorphisms in tumor suppressor genes and oncogenes and risk of hepatocellular carcinoma: a case-control study in an HCC epidemic area within the Han Chinese population. Med Oncol. 2014;31:356. [PMID: 25412941 DOI: 10.1007/s12032-014-0356-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
25 Milani D, Caruso L, Zauli E, Al Owaifeer AM, Secchiero P, Zauli G, Gemmati D, Tisato V. p53/NF-kB Balance in SARS-CoV-2 Infection: From OMICs, Genomics and Pharmacogenomics Insights to Tailored Therapeutic Perspectives (COVIDomics). Front Pharmacol 2022;13:871583. [DOI: 10.3389/fphar.2022.871583] [Reference Citation Analysis]
26 Haque S, Yan XJ, Rosen L, McCormick S, Chiorazzi N, Mongini PK. Effects of prostaglandin E2 on p53 mRNA transcription and p53 mutagenesis during T-cell-independent human B-cell clonal expansion. FASEB J 2014;28:627-43. [PMID: 24145719 DOI: 10.1096/fj.13-237792] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
27 Azzam GA, Frank AK, Hollstein M, Murphy ME. Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model. Cell Cycle 2011;10:1352-5. [PMID: 21566457 DOI: 10.4161/cc.10.9.15344] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
28 Garcia PB, Attardi LD. Illuminating p53 function in cancer with genetically engineered mouse models. Semin Cell Dev Biol 2014;27:74-85. [PMID: 24394915 DOI: 10.1016/j.semcdb.2013.12.014] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
29 Cornut M, Bourdonnay E, Henry T. Transcriptional Regulation of Inflammasomes. Int J Mol Sci 2020;21:E8087. [PMID: 33138274 DOI: 10.3390/ijms21218087] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
30 Gnanapradeepan K, Basu S, Barnoud T, Budina-Kolomets A, Kung CP, Murphy ME. The p53 Tumor Suppressor in the Control of Metabolism and Ferroptosis. Front Endocrinol (Lausanne) 2018;9:124. [PMID: 29695998 DOI: 10.3389/fendo.2018.00124] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 15.0] [Reference Citation Analysis]
31 Omrani-Nava V, Hedayatizadeh-Omran A, Alizadeh-Navaei R, Mokhberi V, Jalalian R, Janbabaei G, Amjadi O, Rahmatpour G, Mozaffari A. TP53 single nucleotide polymorphism (rs1042522) in Iranian patients with coronary artery disease. Biomed Rep 2018;9:259-65. [PMID: 30271603 DOI: 10.3892/br.2018.1121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Gudkov AV, Gurova KV, Komarova EA. Inflammation and p53: A Tale of Two Stresses. Genes Cancer 2011;2:503-16. [PMID: 21779518 DOI: 10.1177/1947601911409747] [Cited by in Crossref: 113] [Cited by in F6Publishing: 111] [Article Influence: 10.3] [Reference Citation Analysis]
33 Li L, Sima X, Bai P, Zhang L, Sun H, Liang W, Liu J, Zhang L, Gao L. Interactions of miR-34b/c and TP53 polymorphisms on the risk of intracranial aneurysm. Clin Dev Immunol 2012;2012:567586. [PMID: 22844323 DOI: 10.1155/2012/567586] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
34 Devi KR, Chenkual S, Majumdar G, Ahmed J, Kaur T, Zonunmawia JC, Mukherjee K, Phukan RK, Mahanta J, Rajguru SK, Mukherjee D, Narain K. TLR2∆22 (-196-174) significantly increases the risk of breast cancer in females carrying proline allele at codon 72 of TP53 gene: a case-control study from four ethnic groups of North Eastern region of India. Tumour Biol 2015;36:9995-10002. [PMID: 26188904 DOI: 10.1007/s13277-015-3795-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
35 Kung CP, Khaku S, Jennis M, Zhou Y, Murphy ME. Identification of TRIML2, a novel p53 target, that enhances p53 SUMOylation and regulates the transactivation of proapoptotic genes. Mol Cancer Res 2015;13:250-62. [PMID: 25256710 DOI: 10.1158/1541-7786.MCR-14-0385] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
36 McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz MJ, Cervera J, Such E, González T, Nevill TJ, Haferlach T, Smith AE, Kulasekararaj A, Mufti G, Karsan A, Maciejewski JP, Sokol L, Epling-Burnette PK, Wei S, List AF. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes. Blood Cancer J 2015;5:e291. [PMID: 25768405 DOI: 10.1038/bcj.2015.11] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
37 Aloi MS, Su W, Garden GA. The p53 Transcriptional Network Influences Microglia Behavior and Neuroinflammation. Crit Rev Immunol 2015;35:401-15. [PMID: 26853851 DOI: 10.1615/critrevimmunol.v35.i5.40] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
38 Yang HJ, Wang M, Wang L, Cheng BF, Lin XY, Feng ZW. NF-κB regulates caspase-4 expression and sensitizes neuroblastoma cells to Fas-induced apoptosis. PLoS One 2015;10:e0117953. [PMID: 25695505 DOI: 10.1371/journal.pone.0117953] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
39 Cooks T, Harris CC, Oren M. Caught in the cross fire: p53 in inflammation. Carcinogenesis 2014;35:1680-90. [PMID: 24942866 DOI: 10.1093/carcin/bgu134] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 11.6] [Reference Citation Analysis]
40 Kung CP, Liu Q, Murphy ME. The codon 72 polymorphism of p53 influences cell fate following nutrient deprivation. Cancer Biol Ther 2017;18:484-91. [PMID: 28475405 DOI: 10.1080/15384047.2017.1323595] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
41 Hu Y, Ge W, Wang X, Sutendra G, Zhao K, Dedeić Z, Slee EA, Baer C, Lu X. Caspase cleavage of iASPP potentiates its ability to inhibit p53 and NF-κB. Oncotarget 2015;6:42478-90. [PMID: 26646590 DOI: 10.18632/oncotarget.6478] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
42 Shatz M, Shats I, Menendez D, Resnick MA. p53 amplifies Toll-like receptor 5 response in human primary and cancer cells through interaction with multiple signal transduction pathways. Oncotarget 2015;6:16963-80. [PMID: 26220208 DOI: 10.18632/oncotarget.4435] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
43 Haupt S, Haupt Y. Cancer and Tumour Suppressor p53 Encounters at the Juncture of Sex Disparity. Front Genet 2021;12:632719. [PMID: 33664771 DOI: 10.3389/fgene.2021.632719] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Sen T, Sen N, Huang Y, Sinha D, Luo ZG, Ratovitski EA, Sidransky D. Tumor protein p63/nuclear factor κB feedback loop in regulation of cell death. J Biol Chem 2011;286:43204-13. [PMID: 22020940 DOI: 10.1074/jbc.M111.257105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
45 Leu JI, Murphy ME, George DL. The p53 Codon 72 Polymorphism Modifies the Cellular Response to Inflammatory Challenge in the Liver. J Liver 2013;2:117. [PMID: 23991369 DOI: 10.4172/2167-0889.1000117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
46 Jazvinšćak Jembrek M, Oršolić N, Mandić L, Sadžak A, Šegota S. Anti-Oxidative, Anti-Inflammatory and Anti-Apoptotic Effects of Flavonols: Targeting Nrf2, NF-κB and p53 Pathways in Neurodegeneration. Antioxidants (Basel) 2021;10:1628. [PMID: 34679762 DOI: 10.3390/antiox10101628] [Reference Citation Analysis]
47 Basu S, Murphy ME. Genetic Modifiers of the p53 Pathway. Cold Spring Harb Perspect Med 2016;6:a026302. [PMID: 27037420 DOI: 10.1101/cshperspect.a026302] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
48 Gudkov AV, Komarova EA. p53 and the Carcinogenicity of Chronic Inflammation. Cold Spring Harb Perspect Med 2016;6:a026161. [PMID: 27549311 DOI: 10.1101/cshperspect.a026161] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
49 Chand HS, Montano G, Huang X, Randell SH, Mebratu Y, Petersen H, Tesfaigzi Y. A genetic variant of p53 restricts the mucous secretory phenotype by regulating SPDEF and Bcl-2 expression. Nat Commun 2014;5:5567. [PMID: 25429397 DOI: 10.1038/ncomms6567] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
50 Barnoud T, Budina-Kolomets A, Basu S, Leu JI, Good M, Kung CP, Liu J, Liu Q, Villanueva J, Zhang R, George DL, Murphy ME. Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 2018;78:5694-705. [PMID: 30115697 DOI: 10.1158/0008-5472.CAN-18-1327] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
51 Zhao Y, Wu L, Yue X, Zhang C, Wang J, Li J, Sun X, Zhu Y, Feng Z, Hu W. A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models. Elife 2018;7:e34701. [PMID: 29557783 DOI: 10.7554/eLife.34701] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
52 Domínguez ER, Orona J, Lin K, Pérez CJ, Benavides F, Kusewitt DF, Johnson DG. The p53 R72P polymorphism does not affect the physiological response to ionizing radiation in a mouse model. Cell Cycle 2017;16:1153-63. [PMID: 28594296 DOI: 10.1080/15384101.2017.1312234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
53 Barabutis N, Dimitropoulou C, Birmpas C, Joshi A, Thangjam G, Catravas JD. p53 protects against LPS-induced lung endothelial barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 2015;308:L776-87. [PMID: 25713322 DOI: 10.1152/ajplung.00334.2014] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
54 Gunaratna RT, Santos A, Luo L, Nagi C, Lambertz I, Spier M, Conti CJ, Fuchs-Young RS. Dynamic role of the codon 72 p53 single-nucleotide polymorphism in mammary tumorigenesis in a humanized mouse model. Oncogene 2019;38:3535-50. [PMID: 30651598 DOI: 10.1038/s41388-018-0630-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
55 Sarkar J, Dominguez E, Li G, Kusewitt DF, Johnson DG. Modeling gene-environment interactions in oral cavity and esophageal cancers demonstrates a role for the p53 R72P polymorphism in modulating susceptibility. Mol Carcinog 2014;53:648-58. [PMID: 23475592 DOI: 10.1002/mc.22019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
56 Perkins ND. The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer. 2012;12:121-132. [PMID: 22257950 DOI: 10.1038/nrc3204] [Cited by in Crossref: 534] [Cited by in F6Publishing: 526] [Article Influence: 53.4] [Reference Citation Analysis]
57 Kim BY, Lee SY, Chung SK. Differential Transcriptional Regulation of Polymorphic p53 Codon 72 in Metabolic Pathways. Int J Mol Sci 2021;22:10793. [PMID: 34639134 DOI: 10.3390/ijms221910793] [Reference Citation Analysis]
58 Katkoori VR, Manne U, Chaturvedi LS, Basson MD, Haan P, Coffey D, Bumpers HL. Functional consequence of the p53 codon 72 polymorphism in colorectal cancer. Oncotarget 2017;8:76574-86. [PMID: 29100333 DOI: 10.18632/oncotarget.20580] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
59 Skhoun H, Khattab M, Belkhayat A, Takki Chebihi Z, Bakri Y, Dakka N, El Baghdadi J. Association of TP53 gene polymorphisms with the risk of acute lymphoblastic leukemia in Moroccan children. Mol Biol Rep 2022. [PMID: 35705773 DOI: 10.1007/s11033-022-07643-3] [Reference Citation Analysis]